Cargando…
Rituximab-induced interstitial lung disease: five case reports
Rituximab (RTX), a mouse/human chimeric anti-CD20 IgG1 monoclonal antibody has been effectively used as a single agent or in combination with chemotherapy regimen to treat lymphoma since 1997. In addition, it has been used to treat idiopathic thrombocytopenic purpura, systemic lupus erythematous, rh...
Autores principales: | Naqibullah, Matiuallah, Shaker, Saher B., Bach, Karen S., Bendstrup, Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629765/ https://www.ncbi.nlm.nih.gov/pubmed/26557260 http://dx.doi.org/10.3402/ecrj.v2.27178 |
Ejemplares similares
-
Emphysema mimicking interstitial lung disease: Two case reports
por: Juhl, Kasper S., et al.
Publicado: (2014) -
Validation of the King’s Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis
por: Prior, Thomas Skovhus, et al.
Publicado: (2019) -
Incidence, prevalence and regional distribution of systemic sclerosis and related interstitial lung Disease: A nationwide retrospective cohort study
por: Knarborg, Malene, et al.
Publicado: (2022) -
Comorbidity and mortality in systemic sclerosis and matched controls: Impact of interstitial lung disease. A population based cohort study based on health registry data
por: Knarborg, Malene, et al.
Publicado: (2023) -
Rituximab-induced interstitial lung disease in a patient with follicular lymphoma: A rare case report
por: Aagre, Suhas, et al.
Publicado: (2015)